Tag - CKPT

Markets

Analysts up Checkpoint Therapeutics PT on positive pivotal data

Analysts for H.C. Wainwright and Cantor Fitzgerald raised their price targets for Checkpoint Therapeutics (NASDAQ:CKPT) to $26 and $20, respectively, after the company reported positive pivotal data with anti-PD-L1...

January 25, 2022

Feature

Checkpoint targeting registration studies by end of 2018

Checkpoint Therapeutics (OTCQX:CKPT) is taking an “aggressive path forward” with its clinical programs and expects to be in registration studies at the end of 2018 with its lead targeted anti-cancer agent, CK-101, and...

April 18, 2017

Tag - CKPT

Analysts up Checkpoint Therapeutics PT on positive pivotal data

Checkpoint targeting registration studies by end of 2018

General

More